Karen Knudsen: I am incredibly proud of this new initiative with Pfizer
Karen Knudsen shared a post on LinkedIn:
“I am incredibly proud of this new initiative with Pfizer: Our goal of ending cancer as we know it, for everyone, including medically underrepresented communities, can only be attained through strong and actionable partnerships with a shared vision.
Our collaboration will help unlock ACS’ full potential in addressing health disparities with measurable, sustainable and systemic solutions to deliver access to high-quality care and treatments for every individual.”
Quoting
“We are proud to announce the launch of “Change the Odds: Uniting to Improve Cancer Outcomes,” in partnership with Pfizer. Today marks a significant milestone on the road to increasing health equity and improved access to cancer care for patients and families in medically underrepresented communities around the country.
For over 100 years we’ve worked to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer. The launch of our new initiative continues this commitment.
With the help of communities across the country, we will Change The Odds and work toward equity in cancer care.
Learn more.”
Source: Karen Knudsen/LinkedIn
Karen E. Knudsen is the CEO of the American Cancer Society (ACS) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health. She also served as president for the Association of American Cancer Institutes (AACI), representing the 102 leading cancer centers in North America, and on the board of directors of the American Association for Cancer Research (AACR). Dr. Knudsen currently holds leadership roles with some of the most important cancer entities in the United States. She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.